Related Experiment Video

Updated: Jul 10, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction

Naylin Bissessor1, Harvey White

  • 1Green Lane Cardiovascular Research Unit,Auckland City Hospital, Auckland, New Zealand.

Vascular Health and Risk Management
|November 1, 2007
PubMed

Insights

Valsartan, an angiotensin receptor blocker, proved as effective as ACE inhibitors for post-myocardial infarction patients. Combination therapy offered no added benefit and increased adverse effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The renin-angiotensin-aldosterone system (RAAS) regulates cardiovascular integrity.
  • Angiotensin II effects, mediated by AT1 receptors, cause vasoconstriction and myocyte growth, leading to cardiac remodeling.
  • Acute myocardial infarction (AMI) management aims to prevent left ventricular dysfunction.

Purpose of the Study:

  • To evaluate the efficacy of angiotensin receptor blockers (ARBs) versus ACE inhibitors in post-AMI patients.
  • To determine if combination therapy with an ARB and ACE inhibitor offers superior outcomes.
  • To review valsartan's role in managing left ventricular dysfunction post-AMI.

Main Methods:

  • The VALIANT trial compared valsartan (ARB) with captopril (ACE inhibitor) in high-risk post-AMI patients.
  • Patients had left ventricular dysfunction or heart failure.
  • Outcomes included cardiovascular morbidity and mortality.

Main Results:

  • Valsartan demonstrated equal efficacy and non-inferiority to captopril.
  • Combination therapy provided no incremental benefit over monotherapy.
  • Combination therapy resulted in a higher incidence of adverse effects.

Conclusions:

  • Valsartan is a viable alternative to ACE inhibitors for high-risk post-AMI patients.
  • ARB monotherapy is effective, and combination therapy offers no additional advantage.
  • Valsartan's pharmacokinetics, dosing, and safety profile are important considerations.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...